Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Sano Genetics has partnered with GenePlaza to link individuals who have used direct-to-consumer (DTC) genetic tests with clinical trials and other research programs, the companies said recently.

Horizon Discovery Group reported recently that its total revenues as reported for the first half of 2019 rose 14 percent, thanks to large increases in revenues from its bioproduction and screening business units.

Novigenix said recently that it has tapped Belgium-based startup bioinformatics firm BioLizard to develop an artificial intelligence-based algorithm to support the transition of its Colox immuno-transcriptomic RT-PCR product onto a new platf

Ginkgo Bioworks recently announced a $290M Series E financing round from new and prior investors.

HTG Molecular Diagnostics announced recently after the close of the market that it intends to offer an undisclosed amount of its common stock in a public offering.

OncoCyte said recently that it has entered into a definitive agreement to acquire Razor Genomics, which developed and markets a prognostic test to assess risk in early-stage lung cancer patients after surgery.

Microbiology testing and diagnostics firm PathoQuest today announced the closing of an €8 million ($8.9 million) financing round.

In diagnostics these days, “a lot of people are after plasma,” reports Jim Averso, vice president, sales and marketing, of I.W. Tremont. “There’s a lot of new research being conducted in plasma-based tests, although it is now very co

Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800 8800 system.

Razor Genomics has developed a test enables the identification of lung cancer patients at high risk for recurrence and allows them to be treated at a time when their cancer can still be responsive to adjuvant chemotherapy.